| Name | CYP2D6 |
|---|---|
| Synonyms | CPD 6; Xenobiotic monooxygenase; Microsomal monooxygenase; Flavoprotein linked monooxygenase; CPD6; CYP2D; CYP2D variant; CYP2D6… |
| Name | piperazine |
|---|---|
| CAS | piperazine |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 15507542 | Raghavan N, Zhang D, Zhu M, Zeng J, Christopher L: Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes. Drug Metab Dispos. 2005 Feb;33(2):203-8. Epub 2004 Oct 26. |
86(1,1,1,6) | Details |
| 14967005 | Hutzler JM, Steenwyk RC, Smith EB, Walker GS, Wienkers LC: Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H--5-yl) methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl] piperazine: kinetic characterization and evidence for apoprotein adduction. Chem Res Toxicol. 2004 Feb;17(2):174-84. |
62(0,2,2,2) | Details |
| 19589229 | Antia U, Tingle MD, Russell BR: Metabolic interactions with piperazine-based 'party pill' drugs. J Pharm Pharmacol. 2009 Jul;61(7):877-82. CONCLUSIONS: Fluorophenylpiperazine, methoxyphenylpiperazine, chlorophenylpiperazine, methylbenzylpiperazine and methylenedioxybenzylpiperazine had significant inhibitory effects on CYP2D6, CYP1A2, CYP3A4, CYP2C19 and CYP2C9 isoenzymes but each piperazine had a different inhibitory profile. |
32(0,1,1,2) | Details |
| 12619053 | Greenblatt DJ, Von Moltke LL, Giancarlo GM, Garteiz DA: Human cytochromes mediating gepirone biotransformation at low substrate concentrations. Biopharm Drug Dispos. 2003 Mar;24(2):87-94. Biotransformation of gepirone to 1-(2-pyrimidinyl)-piperazine (1-PP) and 3'-OH-gepirone, as well as two other hydroxylated metabolites, was studied in vitro using a human liver microsomal preparation and heterologously expressed human CYP3A4 and CYP2D6. |
32(0,1,1,2) | Details |
| 17691920 | Caccia S: N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab. 2007 Aug;8(6):612-22. Once formed they distribute extensively in tissues, including brain which is the target site of most arylpiperazine derivatives, and are then primarily biotransformed by CYP2D6-dependent oxidation to hydroxylates which are excreted as conjugates; only 1-(2-benzisothiazolyl)-piperazine is more susceptible to oxidation than to aromatic hydroxylation. |
32(0,1,1,2) | Details |
| 15228152 | Maurer HH, Kraemer T, Springer D, Staack RF: Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31. In summary, polymorphically expressed CYP2D6 was the major enzyme catalyzing the major metabolic steps of the studied piperazine- and pyrrolidinophenone-derived designer drugs. |
6(0,0,1,1) | Details |
| 14698036 | Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH: Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP). Biochem Pharmacol. 2004 Jan 15;67(2):235-44. In the current study, it was examined whether this reaction may be catalyzed by cytochrome P450 (CYP) 2D6 by comparing TFMPP vs. TFMPP ratios in urine from female Dark Agouti rats, a model of the human CYP2D6 poor metabolizer phenotype (PM), male Dark Agouti rats, an intermediate model, and WI, a model of the human CYP2D6 extensive metabolizer phenotype. |
4(0,0,0,4) | Details |
| 14985146 | Staack RF, Theobald DS, Paul LD, Springer D, Kraemer T, Maurer HH: In vivo metabolism of the new designer drug 1-(4-methoxyphenyl) piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica. 2004 Feb;34(2):179-92. O-demethylation, the major metabolic step, was studied with cDNA-expressed human hepatic cytochrome P450 (CYP) enzymes in pooled human liver microsomes (pHLM) and in single donor human liver microsomes with CYP2D6 poor metabolizer genotype (PM HLM). 4. |
4(0,0,0,4) | Details |
| 15640381 | Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7. mainly underwent N-dealkylation to 1-pyrimidinylpiperazine (1-PP), N-oxidation on the piperazine ring to N-oxide (Bu N-oxide), and hydroxylation to 3'-hydroxybuspirone (3'-OH-Bu), 5-hydroxybuspirone (5-OH-Bu), and 6'-hydroxybuspirone (6'-OH-Bu) in HLMs. Recombinant CYP3A4, CYP3A5, and CYP2D6 exhibited oxidation activities among nine P450 isoforms tested. |
3(0,0,0,3) | Details |
| 17574934 | Staack RF, Paul LD, Schmid D, Roider G, Rolf B: Proof of a 1-(3-chlorophenyl) piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Aug 15;855(2):127-33. Epub 2007 May 29. However, a PM phenotype could also be caused by drug-drug interactions with CYP2D6 inhibitors or substrates such as the co-consumed cocaine and and/or metabolites, respectively. |
2(0,0,0,2) | Details |
| 18238857 | Wen B, Ma L, Rodrigues AD, Zhu M: Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50. Epub 2008 Jan 31. Following incubations with trazodone in the presence of 1-(3'-chlorophenyl) piperazine (m-CPP), a major circulating and pharmacologically active metabolite of several antidepressants including trazodone, nefazodone, and etoperidone, was trapped with to afford the corresponding imine-sulfydryl adducts M4 and M5. |
2(0,0,0,2) | Details |
| 11038163 | Jacobsen W, Christians U, Benet LZ: In vitro evaluation of the disposition of A novel protease inhibitor. Drug Metab Dispos. 2000 Nov;28(11):1343-51. K11777 (N-methyl-piperazine--homoPhe-vinylsulfone-phenyl) is a potent, irreversible protease inhibitor. CYP2D6 metabolized K11777 to its N-desmethyl metabolite with an apparent K (m) (9.2 +/- 1.4 microM) lower than for CYP3A4 (25.0 +/- 4.0 microM) and human liver microsomes. |
2(0,0,0,2) | Details |
| 15056479 | Wojcikowski J, Pichard-Garcia L, Maurel P, Daniel WA: The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208. CYP2C9, CYP2E1 CYP2C19 and CYP2D6 are engaged to a lesser degree in 5-sulphoxidation, while CYP1A2, CYP3A4 and CYP2D6 in perazine N-demethylation (6-10%, depending on the isoform). |
1(0,0,0,1) | Details |
| 18238859 | Minato K, Suzuki R, Asagarasu A, Matsui T, Sato M: Biotransformation of 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl) piperazin-1-yl] butyl}qui nazolin-4 (3H)-one (TZB-30878), a novel (5-HT) 1A agonist/5-HT3 antagonist, in human hepatic cytochrome P450 enzymes. Drug Metab Dispos. 2008 May;36(5):831-40. Epub 2008 Jan 31. Other P450 enzymes, such as a CYP2D6, played a minor role in its metabolism. This compound has quinazoline, piperazine, and quinoline rings. |
1(0,0,0,1) | Details |
| 20148045 | Antia U: 'Party pill' drugs--BZP and TFMPP. N Z Med J. 2009 Dec 11;122(1307):55-68. Their metabolism involves the hepatic P450 enzymes CYP2D6, CYP1A2 and CYP3A4 resulting in inhibited metabolism of other drugs and medicines, as well as compromised metabolism in poor metabolisers for CYP2D6. |
1(0,0,0,1) | Details |
| 11502731 | Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR: Metabolism of vanoxerine, 1-[2-[bis (4-fluorophenyl) methoxy] ethyl]-4-(3-phenylpropyl) piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20. |
0(0,0,0,0) | Details |